Stock AnalizDolby Laboratories, Inc. DLB
Multi-Sector Companies · IPO 2005 · data as of November 13, 2026
Dolby Laboratories, Inc. (DLB) is a company listed in the US with a market value of about $6.0B. In the twelve months to June 26, 2026 it had revenue of $1.4B and net income of $226M, a net margin of 16.7%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (1/5).
Key numbers: a P/E of 27.1, a price to free cash flow of 15.2, 5-year revenue growth of 3% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 7% below the current price.
Score: 2.8 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.2B | $1.2B | $1.1B | $1.1B | $1.0B |
| Net income | $226M | $255M | $262M | $201M | $184M | $310M | $231M | $255M | $42M | $206M | $186M |
| Free cash flow | $393M | $436M | $297M | $337M | $271M | $393M | $278M | $231M | $279M | $278M | $259M |
| EPS (diluted) | $2.35 | $2.62 | $2.69 | $2.05 | $1.81 | $2.97 | $2.25 | $2.44 | $0.39 | $2.00 | $0.62 |
| Net margin | 16.7% | 18.9% | 20.6% | 15.4% | 14.7% | 24.2% | 19.9% | 20.5% | 4.0% | 19.1% | 18.1% |
| ROIC | — | 8.4% | 8.7% | 7.2% | 7.7% | 11.6% | 8.4% | 9.8% | 6.1% | 9.4% | 9.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $79.00, 24% above the current price; targets range from $62.00 to $90.00; the consensus rating is “none”; expected EPS is $4.32 for the fiscal year ending September 30, 2026.
Frequently asked questions
What is Dolby Laboratories’s P/E ratio?
About 27.1, based on the last twelve months of diluted earnings per share (forward P/E about 13.8).
Is Dolby Laboratories stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 7% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Dolby Laboratories pay a dividend?
Yes. The dividend yield is about 2.26%, and it has paid dividends for 10 years in our data.
Is Dolby Laboratories a good stock to buy?
We do not give buy or sell advice. Dolby Laboratories scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.